Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iothalamic Acid SCHEMBL38419 | 1.00 | LMNA (0.56) | LMNASMN1; SMN2TSHRMAPK1KDM4E | |
| Iothalamic Acid SCHEMBL9563103 | 0.98 | LMNA (0.55) | LMNASMN1; SMN2TSHRMAPK1 | |
| SCHEMBL8752140 | 0.89 | LMNA (0.67) | LMNASMN1; SMN2TSHRMAPK1KDM4E | |
| Hydrochloric Acid SCHEMBL8089018 | 0.87 | LMNA (0.65) | LMNASMN1; SMN2TSHRMAPK1KDM4E | |
| Diatrizoic Acid SCHEMBL5960726 | 0.87 | LMNA (0.65) | LMNASMN1; SMN2TSHRMAPK1KDM4E | |
| SCHEMBL21104711 | 0.87 | LMNA (0.50) | LMNASMN1; SMN2TSHRMAPK1 | |
| Diatrizoic Acid SCHEMBL8508 | 0.85 | LMNA (0.67) | LMNASMN1; SMN2TSHRMAPK1KDM4E | |
| Diatrizoic Acid SCHEMBL7615048 | 0.85 | LMNA (0.67) | LMNASMN1; SMN2TSHRMAPK1KDM4E | |
| SCHEMBL11292715 | 0.85 | LMNA (0.36) | LMNASMN1; SMN2TSHRMAPK1KDM4E | |
| SCHEMBL9787545 | 0.85 | LMNA (0.36) | LMNASMN1; SMN2TSHRMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3741381-B1 | A PEPTIDE FOR USE FOR PREVENTION AND TREATMENT OF ACUTE RENAL INJURY | UNIV CORNELL (US) | 2024-04-24 | — | — | EP | claimed |
| US-20220403074-A1 | ETHYLENE/1-HEXENE COPOLYMER HAVING IMPROVED FLEXIBILITY AND PROCESSIBILITY | LG CHEM, LTD. (KR) | 2022-12-22 | — | — | US | claimed |
| EP-3891207-B1 | STEREOCOMPLEXES FOR THE DELIVERY OF ANTI-CANCER AGENTS | TIEN DER YANG (US) | 2022-11-02 | — | — | EP | claimed |
| US-12472301-B2 | Negative pressure therapy system and methods | 3IVE LABS, LLC (US) | 2025-11-18 | — | — | US | disclosed |
| CN-118843428-A | Sensing system and method for diagnosing kidney disease | 德克斯康公司 | 2024-10-25 | — | — | CN | disclosed |
| US-12065558-B2 | Mixed recycled polyolefin resin composition comprising recycled polyolefin resin recovered from waste separator and recycled product using the same | SK INNOVATION CO., LTD. (KR) | 2024-08-20 | — | — | US | disclosed |
| US-20240148913-A1 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE,PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING INNO MEDICINE CO., LTD. (CN) | 2024-05-09 | — | — | US | disclosed |
| CN-117858676-A | Connector for optical coupling of multiplexers | 博尔特医疗有限公司 | 2024-04-09 | — | — | CN | disclosed |
| WO-2024059244-A1 | NEGATIVE PRESSURE THERAPY DEVICES, SYSTEMS, AND TREATMENT METHODS WITH INDWELLING URINARY CATHETERS | 3IVE LABS, LLC (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20240091428-A1 | Negative Pressure Therapy Devices, Systems, And Treatment Methods With Indwelling Urinary Catheters | 3IVE LABS, LLC | 2024-03-21 | — | — | US | disclosed |
| CN-117425446-A | Active alignment system for laser optical coupling | 博尔特医疗有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-116583240-A | Optical analyzer assembly with safety shut-off system for intravascular lithotripsy device | 博尔特医疗有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-20230201165-A1 | JAK INHIBITOR COMPOUND FOR TREATING SEVERE PNEUMONIA | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230068431-A1 | Negative Pressure Therapy System and Methods | 3IVE LABS, LLC | 2023-03-02 | — | — | US | disclosed |
| US-20230060814-A1 | Negative Pressure Therapy System and Methods | 3IVE LABS, LLC | 2023-03-02 | — | — | US | disclosed |
| WO-2023018924-A1 | NEGATIVE PRESSURE THERAPY SYSTEM AND METHODS | 3IVE LABS, LLC (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018922-A1 | NEGATIVE PRESSURE THERAPY SYSTEM AND METHODS | 3IVE LABS, LLC (US) | 2023-02-16 | — | — | WO | disclosed |
| CN-115666434-A | Active alignment system for improving optical coupling of multiplexer of laser-driven intravascular lithotripsy device | 博尔特医疗有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-115334990-A | Optical analyzer assembly and method for intravascular lithotripsy device | 博尔特医疗有限公司 | 2022-11-11 | — | — | CN | disclosed |
| EP-4043519-A1 | POLYETHYLENE COMPOSITION AND METHOD FOR PREPARING SAME | LG Chem, Ltd. (KR) | 2022-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201165-A1 | JAK INHIBITOR COMPOUND FOR TREATING SEVERE PNEUMONIA | JAK1, JAK2, JAK3 | LMNA 4633/4885SMN1; SMN2 3815/4885TSHR 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.